Leerink Swann assumed coverage on shares of Satsuma Pharmaceuticals (NASDAQ:STSA) in a report released on Tuesday morning, The Fly reports. The brokerage issued an outperform rating and a $20.00 target price on the financial services provider’s stock.
A number of other brokerages have also recently commented on STSA. Credit Suisse Group assumed coverage on Satsuma Pharmaceuticals in a research note on Tuesday. They issued an outperform rating and a $16.00 price objective for the company. Svb Leerink assumed coverage on Satsuma Pharmaceuticals in a research note on Tuesday. They issued an outperform rating for the company.
Shares of Satsuma Pharmaceuticals stock opened at $9.73 on Tuesday. Satsuma Pharmaceuticals has a 52 week low of $9.02 and a 52 week high of $19.90.
Satsuma Pharmaceuticals Company Profile
Satsuma Pharmaceuticals, Inc, a clinical-stage biopharmaceutical company, develops a novel therapeutic product for the acute treatment of migraine. Its product candidate is STS101, a drug-device combination of a proprietary dry-powder formulation of dihydroergotamine mesylate, which is in Phase III clinical trials and can be self-administered with a proprietary pre-filled single-use nasal delivery device.
Featured Story: Fundamental Analysis
Receive News & Ratings for Satsuma Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Satsuma Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.